{"id":"NCT00972517","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-29","primaryCompletion":"2010-11-22","completion":"2010-11-22","firstPosted":"2009-09-07","resultsPosted":"2018-09-10","lastUpdate":"2019-06-26"},"enrollment":245,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK investigational vaccine GSK2340272A","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.","primaryOutcome":{"measure":"Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against the Flu A/California/7/2009 (H1N1) Vaccine Strain","timeFrame":"At Day 0, Day 21 and Day 42","effectByArm":[{"arm":"Flu BS1_3-5 Years Group","deltaMin":5.7,"sd":null},{"arm":"Flu BS1_6-9 Years Group","deltaMin":5.2,"sd":null},{"arm":"Flu BS1_10-17 Years Group","deltaMin":9.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":8,"countries":["Germany"]},"refs":{"pmids":["21504774","26176592"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Pain","Erythema","Swelling","Headache","Fatigue"]}}